News

Archives
1 Oct 2011

Recent CAPP2 study shows that 2 yrs of daily Aspirin reduces incidence of primary colorectal cancers by 60% in patients with Lynch syndrome

Recently, the randomised CAPP2 study has updated their results (Burns J et al, Lancet 2011) and has shown that 2 yrs of daily Aspirin reduces incidence of primary colorectal cancers by 60% in patients with Lynch syndrome. Originally reported in the NEJM in 2008 as a negative trial – it has now turned positive on longer follow-up. This trial (together with the updated WHI study involving >100,000 women showing an 18-25% mortality benefit) has turned the spotlight on whether Aspirin should be recommended as primary prevention agent (accompanying editorial Anthony Chan et al, Lancet 2011).

 

Our study however seeks to answer a different question – relating to micrometastasis – and is as relevant as ever. It is to date, still the only secondary prevention study for colorectal cancer